TherapeuticsMD, Inc.

Equities

TXMD

US88338N2062

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-04-26 pm EDT 5-day change 1st Jan Change
1.86 USD -0.53% Intraday chart for TherapeuticsMD, Inc. 0.00% -17.33%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
TherapeuticsMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Knight Therapeutics Announces Launch of Bijuva in Canada MT
Knight Therapeutics Announces Product Launch For IMVEXXY In Canada MT
North American Morning Briefing : Stocks Seen Building on CPI Rally; PPI Data Due DJ
TherapeuticsMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
TherapeuticsMD, Inc. Announces Evaluation of Strategic Alternatives CI
TherapeuticsMD, Inc. Announces Executive Changes CI
TherapeuticsMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell 3000E Growth Index CI
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell Microcap Index CI
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell Microcap Value Index CI
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell 3000E Value Index CI
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell Microcap Growth Index CI
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell 3000E Index CI
TherapeuticsMD, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
TherapeuticsMD, Inc. announced that it expects to receive $5 million in funding from Rubric Capital Management LP CI
TherapeuticsMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
TherapeuticsMD, Inc. Auditor Raises 'Going Concern' Doubt CI
North American Morning Briefing : Stocks Seen -2- DJ
North American Morning Briefing : Traders Reassess -2- DJ
North American Morning Briefing : Some Calm -2- DJ
Cantor Fitzgerald Reinstates TherapeuticsMD at Neutral With $5 Price Target MT
TherapeuticsMd, Inc. Announces Chief Executive Officer Changes CI
TherapeuticsMd, Inc. Announces Executive Changes CI
Chart TherapeuticsMD, Inc.
More charts
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
More about the company
  1. Stock Market
  2. Equities
  3. TXMD Stock
  4. News TherapeuticsMD, Inc.
  5. HC Wainwright Downgrades TherapeuticsMD to Neutral From Buy